Antiphospholipid antibodies: Paradigm in transition

Lawrence L. Horstman, Wenche Jy, Carlos J. Bidot, Yeon S. Ahn, Roger E. Kelley, Robert Zivadinov, Amir H. Maghzi, Masoud Etemadifar, Seyed Ali Mousavi, Alireza Minagar

Research output: Contribution to journalReview article

36 Scopus citations

Abstract

Objectives: This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP. Organization: After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed. Conclusion: The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.

Original languageEnglish (US)
Article number3
JournalJournal of Neuroinflammation
Volume6
DOIs
StatePublished - Jan 20 2009

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Antiphospholipid antibodies: Paradigm in transition'. Together they form a unique fingerprint.

  • Cite this

    Horstman, L. L., Jy, W., Bidot, C. J., Ahn, Y. S., Kelley, R. E., Zivadinov, R., Maghzi, A. H., Etemadifar, M., Mousavi, S. A., & Minagar, A. (2009). Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation, 6, [3]. https://doi.org/10.1186/1742-2094-6-3